Alnylam Pharmaceuticals (ALNY) Earning Somewhat Positive News Coverage, Analysis Finds

News articles about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.8769166955481 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Alnylam Pharmaceuticals (ALNY) opened at $128.05 on Friday. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The stock has a market cap of $12,590.00, a P/E ratio of -24.39 and a beta of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. During the same quarter in the prior year, the business posted ($1.21) EPS. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. research analysts forecast that Alnylam Pharmaceuticals will post -5.21 EPS for the current fiscal year.

ALNY has been the subject of a number of research reports. Nomura initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 14th. They set a “reduce” rating and a $56.00 target price for the company. Instinet initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price for the company. Jefferies Group restated a “buy” rating and issued a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, September 18th. JMP Securities raised their price objective on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, September 20th. Finally, Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, September 20th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $121.20.

In other news, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares in the company, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,075 shares of company stock worth $35,356,089. Company insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/12/alnylam-pharmaceuticals-alny-receiving-somewhat-favorable-press-coverage-analysis-finds.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply